As stated in the report of Credit Suisse, the third quarterly revenue of SH PHARMA (02607.HK) +0.080 (+0.414%) Short selling $643.69K; Ratio 4.148%
shot up 27.7% to RMB 24.703 billion. Excluding special items, the
increasing rate of earnings recorded a year-on-year increase of 13.9%,
an acceleration from 5.8% in the first half of the year. It is believed
that the annual core earnings will record a double-digit growth. The
target price of Shanghai Pharmaceuticals was lifted from $15.04 to $19,
which represents 15x of P/E. The rating was maintained at Neutral.
CITIC Annual Net Profit Up 1.8% to $43.902B; Final Div $0.25 CITIC (00267.HK) -0.160 (-1.447%) Short selling $8.89M; Ratio 25.055% announced that for the year ended December 2017, net profit rose 1.8% yearly to $43.902 billion, with an EPS of $1.51. A final dividend of $0.25 was declared. Profit contribution from financial sector of the company amounted to $39.5 billion, up 3% yearly. CITIC Construction continued to make inroads securing projects, both domestically and internationally, particularly along the Belt and Road corridor.
Comments
Post a Comment